Last reviewed · How we verify
Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing
NA trial testing Text message-based education intervention in COVID-19 Testing Behaviors in 384 participants. Completed in 12 December 2024.
| Lead sponsor | The University of Texas Health Science Center, Houston |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 384 |
| Start date | 3 April 2023 |
| Primary completion | 12 December 2024 |
| Estimated completion | 12 December 2024 |
| Sites | 3 locations across United States |
The University of Texas Health Science Center, Houston
Adults 18 to 89, any sex, with COVID-19 Testing Behaviors. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The number of participants who self-reported use of COVID-19 antigen test or PCR Test using individual-level data in the past 60 days
| Group | Value | 95% CI |
|---|---|---|
| Text Message-based Education Intervention | 31 | |
| Historical Control Group | 22 |
The number of participants who self-reported use of COVID-19 antigen test or PCR Test using individual-level data in the past 60 days
| Group | Value | 95% CI |
|---|---|---|
| Text Message-based Education Intervention | 60 | |
| Historical Control Group | 46 |
| Group | Value | 95% CI |
|---|---|---|
| Text Message-based Education Intervention | 263 | |
| Historical Control Group | 292 |
| Group | Value | 95% CI |
|---|---|---|
| Text Message-based Education Intervention | 259 | |
| Historical Control Group | 12 |
In this Phase III study, the investigators will build off of the Phase II embedded study with some adjustments to the design to address new research priorities that examine an intervention that is network informed and delivered through community health worker interactions plus digitally-delivered intervention content with the goal of increasing COVID-19 testing and vaccination. This model, if proven effective, can be scaled up to address COVID-19 and other future pandemics. The investigators will utilize the sample of intervention priority census block groups (PBGs) used in Phase II and will recruit and enroll participants not previously enrolled in either phase I or II from these PBGs using convenience sampling methods. The investigators will use a historical control group consisting of participants from our control arm in Phase II who completed both their baseline and follow-up surveys embedded in the study.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07074171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing